Matrix Biomed
Matrix Biomed, Inc. is a biopharmaceutical company focused on developing gene-based therapeutics targeting the dysregulation of multiple genes and their interactions within gene regulatory networks. The company's mission is to transform disease models and develop therapies that restore abnormal gene expression to a healthy state, aiming to increase the efficacy of current cancer treatments and reduce side effects. They focus on innovative drug discovery strategies, including targeting master genes like HIF-1 and HIF-2 involved in cancer growth and development, and utilize extensive gene profiling and co-expression networks to identify novel therapeutic approaches.
Industries
Nr. of Employees
small (1-50)
Matrix Biomed
2301 Dupont Dr. Suite 420, Irvine, CA 92612
Patents
Products
Topical ROS-scavenging gel formulation for radiation-induced skin toxicity
Topical gel formulation designed to react with radiation-generated reactive oxygen species and protect normal skin cells from radiation-induced DNA damage; developed for prevention of radiation dermatitis.
Oral solution formulation for prevention of chemotherapy/radiation toxicities
Oral solution formulation of an active small-molecule intended for patients unable to swallow capsules; developed to inhibit hypoxia-related genes and reduce inflammatory and treatment-induced toxicities.
Oral capsule formulation for HIF-targeted oncology indications
Oral capsule formulation of a small-molecule HIF inhibitor intended for systemic treatment of solid tumors and evaluated in Phase II clinical studies for glioblastoma and prostate cancer.
Topical ROS-scavenging gel formulation for radiation-induced skin toxicity
Topical gel formulation designed to react with radiation-generated reactive oxygen species and protect normal skin cells from radiation-induced DNA damage; developed for prevention of radiation dermatitis.
Oral solution formulation for prevention of chemotherapy/radiation toxicities
Oral solution formulation of an active small-molecule intended for patients unable to swallow capsules; developed to inhibit hypoxia-related genes and reduce inflammatory and treatment-induced toxicities.
Oral capsule formulation for HIF-targeted oncology indications
Oral capsule formulation of a small-molecule HIF inhibitor intended for systemic treatment of solid tumors and evaluated in Phase II clinical studies for glioblastoma and prostate cancer.
Services
Case-by-case review of expanded access requests for investigational drugs against predefined eligibility criteria; initial review response within a stated timeline.
Design and execution of randomized Phase II/IIb and Phase III trials including endpoint selection, randomization schemes, and multi-site enrollment for prevention of treatment toxicities and therapeutic efficacy.
Case-by-case review of expanded access requests for investigational drugs against predefined eligibility criteria; initial review response within a stated timeline.
Design and execution of randomized Phase II/IIb and Phase III trials including endpoint selection, randomization schemes, and multi-site enrollment for prevention of treatment toxicities and therapeutic efficacy.
Expertise Areas
- Gene regulatory network analysis
- Gene-based therapeutics development
- Oncology supportive-care and toxicity prevention
- Clinical trial management (Phase II/III)
Key Technologies
- Gene expression profiling (gene arrays)
- Gene co-expression and regulatory network modeling
- Small-molecule therapeutic development
- Reactive oxygen species (ROS) scavenging chemistry
News & Updates
MBM-10-01 Phase II/III Clinical Trial for Ataxia Telangiectasia
Clinical trial for the treatment of Ataxia Telangiectasia, activating genes NRF2 and BDNF to prevent DNA damage and neurodegeneration.
MBM-02 clinical trial for prostate cancer
FDA-approved phase II trial using MBM-02 to treat prostate cancer by inhibiting HIF-1 and HIF-2, and reducing tumor vascularity.
MBM-02 for glioblastoma multiforme
Phase II studies on MBM-02 to increase survival and reduce side effects in glioblastoma patients.
Prevention of toxicities in cancer treatments
Development of topical gels (MTS-01, MTS-02) to prevent radiation-induced dermatitis and other toxicities.
MBM-10-01 Phase II/III Clinical Trial for Ataxia Telangiectasia
Clinical trial for the treatment of Ataxia Telangiectasia, activating genes NRF2 and BDNF to prevent DNA damage and neurodegeneration.
MBM-02 clinical trial for prostate cancer
FDA-approved phase II trial using MBM-02 to treat prostate cancer by inhibiting HIF-1 and HIF-2, and reducing tumor vascularity.
MBM-02 for glioblastoma multiforme
Phase II studies on MBM-02 to increase survival and reduce side effects in glioblastoma patients.
Prevention of toxicities in cancer treatments
Development of topical gels (MTS-01, MTS-02) to prevent radiation-induced dermatitis and other toxicities.